RNS Number: 4130G Renalytix PLC 01 October 2024

Renalytix plc ("Renalytix" or the "Company")

Audited US GAAP financial results for the fiscal year ended 30 June 2024

LONDON and NEW YORK, 1 October, 2024- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, confirms that it has published its audited US GAAP financial results for the fiscal year ended 30 June 2024 as disclosed in its Form 10-K filed with the Securities and Exchange Commission.

The consolidated balance sheet of as of June 30, 2024, and the related consolidated statements of operations and comprehensive loss, shareholders' equity (deficit), and cash flows for the year ended June 30, 2024, are provided further below.

The full announcement is available to view on the Company website: https://investors.renalytix.com/financials-and-filings/sec-filings

Audited Full Year Fiscal 2024 Results under IFRS will be issued in due course.

For further information, please contact:

 Renalytix plc
 www.renalytix.com

 James McCullough, CEO
 Via Walbrook PR

Stifel (Nominated Adviser and Joint Broker)
Nicholas Moore / Nick Harland / Ben Good
Tel: 020 7710 7600

Oberon Capital (Joint Broker) Tel: 020 3179 5300

Mike Seabrook / Nick Lovering

Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Alice Woodings / Charlotte Edgar Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

CapComm Partners

Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

Important Notices

Stifel Nicolaus Europe Limited and Oberon Investments Limited are authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA") and are acting exclusively for the Company and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than Renalytix for providing the protections afforded to its clients nor for providing advice in relation to the subject matter of this announcement.

I his announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

This announcement (including any information incorporated by reference in this announcement) and other information published by the Company contain statements about the Company that are or may be deemed to be forward looking statements. Without limitation, any statements preceded or followed by or that include the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or words or terms of similar substance or the negative thereof, may be forward looking statements.

These forward-looking statements are not guarantees of future performance. Such forward-looking statements involve known and unknown risks and uncertainties that could significantly affect expected results and are based on certain key assumptions. Many factors could cause actual results to differ materially from those projected or implied in any forward-looking statements. Due to such uncertainties and risks, readers should not rely on such forward-looking statements, which speak only as of the date of this announcement. The Company disclaims any obligation or responsibility to update publicly or review any forward-looking or other statements contained in this announcement, except as required by applicable law.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

RENALYTIX PLC CONSOLIDATED BALANCE SHEETS

	June 30,	June 30,
(in thousands, except share and per share data)	2024	2023
Assets		
Current assets:		
Cash and cash equivalents	4,680	24,682
Accounts receivable	722	776
Prepaid expenses and other current assets	716	1,424
Total current assets	6,118	26,882
Property and equipment, net	216	1,027
Right-of-use asset	-	159
Investment in VericiDx	698	1,460
Other Assets	940	1,101
Total assets	7,972	30,629
Liabilities and Shareholders' Equity (Deficit)		
Current liabilities:		
Accounts payable	1,590	1,485
Accounts payable - related party	1,018	1,451
Accrued expenses and other current liabilities	3,354	6,644
Accrued expenses - related party	1,329	1,963
Current lease liability	45	130
Convertible notes-current	4,159	4,463
Total current liabilities	11,495	16,136
Convertible notes-noncurrent	4,331	7,485
Noncurrent lease liability	-	41
Total liabilities	15,826	23,662
Commitments and contingencies (Note 10)		
Shareholders' equity (deficit):		
Ordinary shares, £0.0025 par value per share: 161,842,057 shares		
authorized; 154,368,191 and 93,781,478 shares issued and		
outstanding at June 30, 2024 and June 30, 2023, respectively	478	286
Additional paid-in capital	204,893	186,456
Accumulated other comprehensive loss	(1,443)	(1,450)
Accumulated deficit	(211,782)	(178,325)
Total shareholders' equity (deficit)	(7,854)	6,967
Total liabilities and shareholders' equity (deficit)	7 077	20 E20

RENALYTIX PLC CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Twelve Months Ended	Twelve Months Ended
(in thousands, except share and per share data)	June 30, 2024	June 30, 2023
Revenue	2,289	3,403
Cost of revenue	2,133	2,683
Gross profit	156	720
Operating expenses:		
Research and development	9,290	14,298
General and administrative	<i>19,751</i>	28,662
Impairment loss on property, equipment and other long-lived assets	723	-
Performance of contract liability to affiliate		(19)
Total operating expenses	29,764	42,941
Loss from operations	(29,608)	(42,221
Equity in net losses of affiliate	-	(9)
Foreign currency gain, net	163	358
Fair value adjustment to VericiDx investment	(505)	(1,282)
Fair value adjustment to convertible notes	(3,751	(3,107)
Other income, net	249	656
Net loss before income taxes	(33,452)	(45,605)
Income tax expense	(4)	(2)
Net loss	(33,456)	(45,607
Net loss per ordinary share-basic	(0.31	(0.55)
Net loss per ordinary share-diluted	(0.31	(0.55)
Weighted average ordinary shares-basic	108,179,366	82,210,050
Weighted average ordinary shares-diluted	108,179,366	82,210,050
Other comprehensive income (loss):		
Changes in the fair value of the convertible notes	305	(337)
Foreign exchange translation adjustment	(298)	(198)
Comprehensive loss	(33,449)	(46,142)

RENALYTIX PLC CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)

(in thousands, except share data) Shares Amount capital loss deficit equity (deficit) Balance at June 30, 2022 74,760,432 228 164,012 (915) (132,718) 30,607 Shares issued under the Securities Purchase Agreement 18,722,960 57 19,248 - - 19,305 Shares issued under the employee share purchase plan 298,086 1 260 - - 261 Stock-based compensation expense - - 2,936 - - 2,936 Changes in the fair value of the convertible notes - - - (1337) - 2,936 Changes in the fair value of the convertible notes - - - (198) -		0.1	,	Additional	Accumulated other		Total
Balance at June 30, 2022 74,760,432 228 164,012 (915) (132,718) 30,607		Ordinary shares		paid-in	comprehensive	Accumulated	shareholders'
Shares issued under the Securities Purchase Agreement 18,722,960 57 19,248 - - 19,305 Shares issued under the employee share purchase plan 298,086 1 260 - - 261 Stock-based compensation expense - - 2,936 - - 2,936 Changes in the fair value of the convertible notes - - - (198) - 2,936 Changes in the fair value of the convertible notes - - - (198) - 2,936 Currency translation adjustments - - - (198) - (198 Net loss - - - - (198) - (198) Net loss - - - - (198) - (198) Net loss - - - - (198) (198) (198) Net loss 93,781,478 286 186,456 (1,450) (178,325) 6,967 Shares issued under the Securit							
Agreement 18,722,960 57 19,248 - - 19,305 Shares issued under the employee share purchase plan 298,086 1 260 - - 261 Stock-based compensation expense - - 2,936 - - 2,936 Changes in the fair value of the convertible notes - - - 2,936 - - 2,936 Changes in the fair value of the convertible notes - - - - (337) - (337 Currency translation adjustments - - - - (198) - (198 Net loss - - - - (198) - (198) - (198) - (198) - (198) - (198) - (198) - (198) - (198) - (198) - (198) - (198) - - - - - - - - - - <t< td=""><td>Balance at June 30, 2022</td><td>74,760,432</td><td>228</td><td>164,012</td><td>(915)</td><td>(132,718)</td><td>30,607</td></t<>	Balance at June 30, 2022	74,760,432	228	164,012	(915)	(132,718)	30,607
Shares issued under the employee share purchase plan 298,086 1 260 - - 261 Stock-based compensation expense - - 2,936 - - 2,936 Changes in the fair value of the convertible notes - - - - (337) - (337) Currency translation adjustments - - - - (198) - (198 Net loss - - - - - (198) - (198 Net loss - - - - - (198) - (198 Net loss - - - - (198) - (198 Net loss - - - - (198) - (198 Net loss 93,781,478 286 186,456 (1,450) (178,325) 6,967 Shares issued under the Securities Purchase 50,801,873 161 11,656 - - - 5,008 <td>Shares issued under the Securities Purchase</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Shares issued under the Securities Purchase						
purchase plan 298,086 1 260 - - 261 Stock-based compensation expense - - 2,936 - - 2,936 Changes in the fair value of the convertible notes - - - - (337) - (337) Currency translation adjustments - - - - (198) - (198 Net loss - - - - (198) - (198 Net loss - - - - (198) - (198 Net loss - - - - (198) - (198 Net loss - - - - (198) - (198 Net loss - - - - (198 - - (198 Net loss - - - - - - - - - - - - - - <td>Agreement</td> <td>18,722,960</td> <td><i>57</i></td> <td>19,248</td> <td>-</td> <td>-</td> <td>19,305</td>	Agreement	18,722,960	<i>57</i>	19,248	-	-	19,305
Stock-based compensation expense - 2,936 - 2,936 Changes in the fair value of the convertible notes - - - (337) - (337) Currency translation adjustments - - - - (198) - (198) - (198) - (198) - (198) - (198) - (198) - (198) - (198) - - (198) - - (198) -	Shares issued under the employee share						
Changes in the fair value of the convertible notes (337) - (337) Currency translation adjustments (198) - (198) Net loss (198) (45,607) (45,007) (45,007) (45,007) (45,007) (45,007) (45,007) (45,007) (45,007) (45,007) (4	purchase plan	298,086	1	260	-	-	261
Currency translation adjustments	Stock-based compensation expense	-	-	2,936	-	-	2,936
Currency translation adjustments - - - - (198) - - (198) -	Changes in the fair value of the convertible						
Net loss	notes	-	-	-	(337)	-	(337
Balance at June 30, 2023 93,781,478 286 186,456 (1,450) (178,325) 6,967 Shares issued under the Securities Purchase Agreement, net of offering costs 50,801,873 161 11,656 - - 11,817 Shares issued for repayment of convertible bond 9,523,972 30 4,978 - - 5,008 Vesting of RSUs 185,540 1 - - - 1 Shares issued under the employee share purchase plan 75,328 - 93 - - 93 Stock-based compensation expense - - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - 305 - 305 Currency translation adjustments - - - - (298) - (298) Net loss - - - - - (33,456) (33,456)	Currency translation adjustments	-	-	-	(198)	-	(198
Shares issued under the Securities Purchase 50,801,873 161 11,656 - - 11,817 Shares issued for repayment of convertible bond 9,523,972 30 4,978 - - 5,008 Vesting of RSUs 185,540 1 - - - 1 Shares issued under the employee share purchase plan 75,328 - 93 - - 93 Stock-based compensation expense - - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - (33,456) (33,456) (33,456)	Net loss	-	-	-		(45,607)	(45,607
Agreement, net of offering costs 50,801,873 161 11,656 11,817 Shares issued for repayment of convertible bond 9,523,972 30 4,978 5,008 Vesting of RSUs 185,540 1 1 Shares issued under the employee share purchase plan 75,328 - 93 93 Stock-based compensation expense - 1,710 1,710 Changes in the fair value of the convertible notes 305 - 305 Currency translation adjustments (298) Net loss (33,456) (33,456)	Balance at June 30, 2023	93,781,478	286	186,456	(1,450)	(178,325)	6,967
Shares issued for repayment of convertible bond 9,523,972 30 4,978 - - 5,008 Vesting of RSUs 185,540 1 - - - 1 Shares issued under the employee share purchase plan 75,328 - 93 - - 93 Stock-based compensation expense - - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - (33,456) (33,456)	Shares issued under the Securities Purchase						
bond 9,523,972 30 4,978 - - 5,008 Vesting of RSUs 185,540 1 - - - 1 Shares issued under the employee share purchase plan 75,328 - 93 - - 93 Stock-based compensation expense - - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - - (33,456) (33,456)	Agreement, net of offering costs	50,801,873	161	11,656	-	-	11,817
Vesting of RSUs 185,540 1 - - - 1 Shares issued under the employee share purchase plan 75,328 - 93 - - 93 Stock-based compensation expense - - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - - (33,456) (33,456)	Shares issued for repayment of convertible						
Shares issued under the employee share purchase plan 75,328 - 93 - - 93 Stock-based compensation expense - - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - (33,456) (33,456)	bond	9,523,972	30	4,978	-	-	5,008
purchase plan 75,328 - 93 - - 93 Stock-based compensation expense - - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - - 305 - 305 Currency translation adjustments - - - - (298) - (298) Net loss - - - - - - (33,456) (33,456)	Vesting of RSUs	185,540	1	-	-	-	1
Stock-based compensation expense - 1,710 - - 1,710 Changes in the fair value of the convertible notes - - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - - (33,456) (33,456)	Shares issued under the employee share						
Changes in the fair value of the convertible notes - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - (33,456) (33,456)	purchase plan	75,328	-	93	-	-	93
notes - - - 305 - 305 Currency translation adjustments - - - (298) - (298) Net loss - - - - - (33,456) (33,456)	Stock-based compensation expense	-	-	1,710	-	-	1,710
Currency translation adjustments - - (298) - (298) Net loss - - - - (33,456) (33,456)	Changes in the fair value of the convertible						
Net loss <u> (33,456)</u> (33,456	notes	-	-	-	305	-	305
	Currency translation adjustments	-	-	-	(298)	-	(298
Perlance of time 20, 2024	Net loss	-	-	-	-	(33,456)	(33,456
bulance at June 30, 2024 154,368,191 478 204,893 (1,443) (211,782) (7,854)	Balance at June 30, 2024	154,368,191	478	204,893	(1,443)	(211,782)	(7,854)

RENALYTIX PLC CONSOLIDATED STATEMENTS OF CASH FLOWS

Net loss (33,456) (45,607) Adjustments to reconcile net loss to net cash used in operating activities: 364 508 Depreciation and amorization 364 508 Impairment loss on property, equipment and other long-lived assets 723 - Stock-based compensation 1,710 2,932 Equity in losses of affiliate - 9 Reduction of Kantaro liability - (55) Fair value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized loss on sale of ordinary shares in VericiDx 135 - Realized foreign exchange gain (132) - Fair value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 4 125 Accounts propable receivable 54 125 129 Prepaid expenses and other current assets 788 1,299 Receivable from affiliates - 7.5 Accounts pa	(in thousands)	Year Ended June 30, 2024	Year Ended June 30, 2023
Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Impairment loss on prosperty, equipment and other long-lived assets 723 5tock-based compensation 1,710 2,932 Equity in losses of affiliate Reduction of Kantaro liability - (55) Fair value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized foreign exchange gain Realized foreign exchange gain Realized foreign exchange gain Ron cash lease expense 67 106 Foir value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: Accounts receivable 54 125 Prepaid expenses and other current assets 798 Receivable from affiliates 67 75 Accounts payable - related party (433) 368 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (46) Net cash used in operating activities Cash flows from investing activities Purchase of equipment Net cash used in investing activities Payment of convertible notes principal Proceeds from issuance of ordinary shares in Private Placement Net cash used in investing activities Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares in Private Placement Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan Payment of offering costs (1,716) (1,651) Cash and cash equivalents, beginning of year (2,682 4,682 4,683 Cash and cash equivalents, beginning of year (2,682 4,682 5,682 5,782 5,783 5,784 5,785	Cash flows from operating activities:		
Depreciation and amortization 364 508 Impairment loss on property, equipment and other long-lived assets 723 - Stock-based compensation 1,710 2,932 Equity in losses of affiliate - 9 Reduction of Kontaro liability - (55) Fair value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized foreign exchange gain (132) - Foir value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 67 106 Accounts receivable 54 125 128 1299 Prepaid expenses and other current assets 78 1,299 1299 1299 1299 128 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 1299 <	Net loss	(33,456)	(45,607)
Impairment loss on property, equipment and other long-lived assets 723 Stock-based compensation 1,710 2,932 Equity in losses of affiliate - 9 Reduction of Kantaro liability - (55) Foir value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized foreign exchange gain (132) - Foir value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 75 Accounts receivable 54 125 Prepaid expenses and other current assets 798 1,299 Receivable from affiliates - 75 Accounts payable 106 80 Accounts payable - related party (433) 368 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (46) Net cash used in operating activities (30,111) (34,085) Cash flows from investing activities - (49) - Poyment of convertible notes principal (1,660) <t< td=""><td>Adjustments to reconcile net loss to net cash used in operating activities:</td><td></td><td></td></t<>	Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation 1,710 2,932 Equity in losses of affiliate - 9 Reduction of Kantaro liability - (55) Fair value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized foreign exchange gain (132) - Fair value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 76 Accounts receivable 54 125 Prepaid expenses and other current assets 798 1,299 Accounts from affiliates - 75 Accounts payable 106 80 Accounts payable related party (433) 368 Accounts payable related party (331) 3,397 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (46) Net cash flows from	Depreciation and amortization	364	508
Equity in losses of affiliate - 9 Reduction of Kantaro liability - (55) Fair value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized foreign exchange gain (132) - Fair value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 76 Accounts receivable 54 125 Prepaid expenses and other current assets 798 1,299 Receivable from affiliates - 75 Accounts payable 106 80 Accounts payable - related party (433) 368 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (46) Net cash used in operating activities (30,111) (34,085) Cash flows from investing activities - (46)	Impairment loss on property, equipment and other long-lived assets	723	-
Reduction of Kantaro liability - (55) Foir value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized loss on sale of ordinary shares in VericiDx 135 - Realized foreign exchange gain (132) - Fair value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 67 106 Accounts receivable 54 125 - 75 Receivable from affiliates - 75 Accounts payable and other current assets 78 1,299 Receivable from affiliates - 75 Accounts payable related party (433) 368 Accounts payable related party (433) 368 Accounts payable related party (635) 451 Deferred revenue (404) 3,397 Accrued expenses - related party (635) 451 Net cash used in investing activities (30,111) (34,085) <td< td=""><td>Stock-based compensation</td><td>1,710</td><td>2,932</td></td<>	Stock-based compensation	1,710	2,932
Fair value adjustment to VericiDx investment 505 1,282 Unrealized foreign exchange gain - (1,008) Realized loss on sale of ordinary shares in VericiDx 135 - Realized foreign exchange gain (132) - Fair value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 76 Accounts receivable 54 125 Prepaid expenses and other current assets 798 1,299 Receivable from affiliates - 75 Accounts payable 106 80 Accounts payable - related party (433) 368 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses related party (635) 451 Deferred revenue - (46) Net cash used in operating activities (30,111) (34,085) Cash flows from investing activities - - Purchase of equipment (4) - <t< td=""><td>Equity in losses of affiliate</td><td>-</td><td>9</td></t<>	Equity in losses of affiliate	-	9
Unrealized foreign exchange gain Realized loss on sale of ordinary shares in VericiDx Realized foreign exchange gain Fair value adjustment to convertible debt, net interest paid S,502 1,999 Non cash lease expense For value adjustment to convertible debt, net interest paid S,502 Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Receivable from affiliates Foreign exchange gain For value adjustment assets and liabilities: Receivable from affiliates Foreign exchange gain For value expenses and other current assets Foreign exchape from affiliates Foreign exchape from investing activities Foreign exchape from investing activities Foreign exchape from financing activities Foreign exchape from affiliates Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign exchape from the issuance of ordinary shares under employee share Foreign	Reduction of Kantaro liability	-	(55)
Realized loss on sale of ordinary shares in VericiDx Realized foreign exchange gain (132) - Fair value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: Accounts receivable 54 125 Prepaid expenses and other current assets 798 1,299 Receivable from affiliates 63 63 63 64 65 60 60 60 60 60 60 60 60 60 60 60 60 60	Fair value adjustment to VericiDx investment	505	1,282
Realized foreign exchange gain (132) - Fair value adjustment to convertible debt, net interest paid 3,502 1,999 Non cash lease expense 67 106 Changes in operating assets and liabilities: - 78 125 Accounts receivable 54 125 1299 1290 1290 1290 1290 1290 1290 1290 1290 1290 1290 1290 1290 1290 1290	Unrealized foreign exchange gain	-	(1,008)
Fair value adjustment to convertible debt, net interest paid Non cash lease expense Changes in operating assets and liabilities: Accounts receivable Sereivable from affiliates Accounts payable 106 Accounts payable 107 Accrued expenses and other current liabilities 103,419 Accrued expenses - related party 103,4085 Accrued expenses in investing activities 103,4085 Accrued expenses - related party 103,4085 Accrued expenses - related party 103,4085 Accrued expenses in investing activities 103,4085 Accrued expenses in form obtaining right-of-use assets 104,680 Accrued expenses and 103,4085 Accrued expenses and 104,680 Accrued e	Realized loss on sale of ordinary shares in VericiDx	135	-
Non cash lease expense Changes in operating assets and liabilities: Accounts receivable Accounts receivable Prepaid expenses and other current assets Prepaid expenses and other current liabilities arising and financing activities Prepaid expenses and other current liabilities arising from obtaining right-of-use assets Prepaid expenses and textification and convertible debt Prepaid expenses and textification and convertible debt Prepaid expenses and textification and textificatio	Realized foreign exchange gain	(132)	-
Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid expenses and other current assets Accounts payable 106 80 Accounts payable - related party 106 Accounts payable - related party 106 Accrued expenses and other current liabilities 107 Accrued expenses and other current liabilities 108 Accrued expenses - related party 109 Accrued expenses and other current liabilities 109 Accrued expenses - related party 109 Accrued expen	Fair value adjustment to convertible debt, net interest paid	3,502	1,999
Accounts receivable 54 125 Prepaid expenses and other current assets 798 1,299 Receivable from affiliates - 75 Accounts payable 106 80 Accounts payable - related party (433) 368 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (46) Net cash used in operating activities (30,111) (34,085) Cash flows from investing activities: - - Purchase of equipment (4) - Net cash used in investing activities: - - Purchase of equipment investing activities: - - Purchase of equipment of convertible notes principal (1,660) (3,180) Proceeds from financing activities: - - Payment of convertible notes principal (1,660) (3,180) Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (Non cash lease expense	67	106
Prepaid expenses and other current assets Receivable from affiliates Recounts payable foliates Recounts payable - related party Receivable related party Receivable related party Recounts payable - related party Recrued expenses and other current liabilities Recrued expenses - related party Re	Changes in operating assets and liabilities:		
Receivable from affiliates - 75 Accounts payable 106 80 Accounts payable - related party (433) 368 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (465) Net cash used in operating activities (30,111) (34,085) Cash flows from investing activities: Purchase of equipment (4) Net cash used in investing activities: Payment of convertible notes principal (1,660) (3,180) Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (1377) 1,048 Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249	Accounts receivable	54	125
Accounts payable 106 80 Accounts payable - related party (433) 368 Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (46) Net cash used in operating activities (30,111) (34,085) Cash flows from investing activities: Purchase of equipment (4) - Net cash used in investing activities (4) - Net cash used in investing activities (4) - Cash flows from financing activities: Payment of convertible notes principal (1,660) (3,180) Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (137) 1,048 Net decrease in cash and cash equivalents (20,000) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -	Prepaid expenses and other current assets	798	1,299
Accounts payable - related party Accounts payable - related party Accound expenses and other current liabilities Accrued expenses - related party Accrued party Accrue	Receivable from affiliates	-	<i>7</i> 5
Accrued expenses and other current liabilities (3,419) 3,397 Accrued expenses - related party (635) 451 Deferred revenue - (46) Net cash used in operating activities (30,111) (34,085) Cash flows from investing activities: Purchase of equipment (4) - Net cash used in investing activities (4) - Net cash used in investing activities (4) - Cash flows from financing activities: Payment of convertible notes principal (1,660) (3,180) Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (137) 1,048 Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 24,682 41,333 Cash and cash equivalents, end of year 24,682 5upplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -	Accounts payable	106	80
Accrued expenses - related party Deferred revenue Net cash used in operating activities: Cash flows from investing activities: Purchase of equipment Net cash used in investing activities: Payment of convertible notes principal Proceeds from issuance of ordinary shares in Private Placement Proceeds from the issuance of ordinary shares under employee share purchase plan Pet cash provided by financing activities 10,250 Effect of exchange rate changes on cash Net decrease in cash and cash equivalents Cash and cash equivalents, beginning of year Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets Cash paid for interest on convertible debt 10,260 10,340 10,340 10,340 10,340 10,340 10,340 10,460 10,4	Accounts payable - related party	(433)	368
Deferred revenue Net cash used in operating activities Cash flows from investing activities: Purchase of equipment Net cash used in investing activities Cash flows from financing activities Cash flows from financing activities Payment of convertible notes principal Proceeds from issuance of ordinary shares in Private Placement Payment of offering costs Payment of offering costs Payment of offering costs Proceeds from the issuance of ordinary shares under employee share purchase plan Pet cash provided by financing activities Effect of exchange rate changes on cash Net decrease in cash and cash equivalents Pash and cash equivalents, beginning of year Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt - (46) (30,011) (34,085) (4) - (4)	Accrued expenses and other current liabilities	(3,419)	3,397
Deferred revenue Net cash used in operating activities Cash flows from investing activities: Purchase of equipment Net cash used in investing activities Cash flows from financing activities Cash flows from financing activities Payment of convertible notes principal Proceeds from issuance of ordinary shares in Private Placement Payment of offering costs Payment of offering costs Payment of offering costs Proceeds from the issuance of ordinary shares under employee share purchase plan Pet cash provided by financing activities Effect of exchange rate changes on cash Net decrease in cash and cash equivalents Pash and cash equivalents, beginning of year Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt - (46) (30,011) (34,085) (4) - (4)	Accrued expenses - related party	(635)	451
Net cash used in operating activities Cash flows from investing activities: Purchase of equipment Net cash used in investing activities Cash flows from financing activities Payment of convertible notes principal Proceeds from issuance of ordinary shares in Private Placement Payment of offering costs Payment of offering costs Proceeds from the issuance of ordinary shares under employee share purchase plan Net cash provided by financing activities Effect of exchange rate changes on cash Net decrease in cash and cash equivalents Cash and cash equivalents, beginning of year Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt	Deferred revenue	-	(46)
Purchase of equipment Net cash used in investing activities Cash flows from financing activities: Payment of convertible notes principal Proceeds from issuance of ordinary shares in Private Placement Proceeds from the issuance of ordinary shares under employee share purchase plan Pet cash provided by financing activities Pfect of exchange rate changes on cash Net decrease in cash and cash equivalents Possible for the issuance of ordinary shares under employee share purchase plan Pet cash provided by financing activities Pfect of exchange rate changes on cash Pet decrease in cash and cash equivalents Pet decrease in cash equivalents Pet decrease in cash and cash equivalents Pet decrease in cash and cash equivalents Pet decrease in cash equivalents Pet d	Net cash used in operating activities	(30,111)	(34,085)
Net cash used in investing activities (4) — Cash flows from financing activities: Payment of convertible notes principal (1,660) (3,180) Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (137) 1,048 Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -	Cash flows from investing activities:		
Cash flows from financing activities: Payment of convertible notes principal (1,660) (3,180) Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (137) 1,048 Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -	Purchase of equipment	(4)	<u>-</u>
Payment of convertible notes principal (1,660) (3,180) Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (137) 1,048 Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -	Net cash used in investing activities	(4)	
Proceeds from issuance of ordinary shares in Private Placement 13,533 20,296 Payment of offering costs (1,716) (991) Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (137) 1,048 Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -	Cash flows from financing activities:		
Payment of offering costs(1,716)(991)Proceeds from the issuance of ordinary shares under employee share purchase plan93261Net cash provided by financing activities10,25016,386Effect of exchange rate changes on cash(137)1,048Net decrease in cash and cash equivalents(20,002)(16,651)Cash and cash equivalents, beginning of year24,68241,333Cash and cash equivalents, end of year4,68024,682Supplemental noncash investing and financing activities:Noncash lease liabilities arising from obtaining right-of-use assets-265Cash paid for interest on convertible debt249-		(1,660)	(3,180)
Proceeds from the issuance of ordinary shares under employee share purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249	Proceeds from issuance of ordinary shares in Private Placement	13,533	20,296
purchase plan 93 261 Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets 249 -	Payment of offering costs	(1,716)	(991)
Net cash provided by financing activities 10,250 16,386 Effect of exchange rate changes on cash (137) 1,048 Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets 265 Cash paid for interest on convertible debt 249	Proceeds from the issuance of ordinary shares under employee share	02	264
Effect of exchange rate changes on cash(137)1,048Net decrease in cash and cash equivalents(20,002)(16,651)Cash and cash equivalents, beginning of year24,68241,333Cash and cash equivalents, end of year4,68024,682Supplemental noncash investing and financing activities:Noncash lease liabilities arising from obtaining right-of-use assets-265Cash paid for interest on convertible debt249-	•		
Net decrease in cash and cash equivalents (20,002) (16,651) Cash and cash equivalents, beginning of year 24,682 41,333 Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -			
Cash and cash equivalents, beginning of year24,68241,333Cash and cash equivalents, end of year4,68024,682Supplemental noncash investing and financing activities:Noncash lease liabilities arising from obtaining right-of-use assets-265Cash paid for interest on convertible debt249-			
Cash and cash equivalents, end of year 4,680 24,682 Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249			
Supplemental noncash investing and financing activities: Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -			
Noncash lease liabilities arising from obtaining right-of-use assets - 265 Cash paid for interest on convertible debt 249 -	Cash and cash equivalents, end of year	4,680	24,682
Cash paid for interest on convertible debt 249 -	Supplemental noncash investing and financing activities:		
· · ·	Noncash lease liabilities arising from obtaining right-of-use assets	-	265
Issuance of shares for debt repayment (5,008) -	•	249	-
	Issuance of shares for debt repayment	(5,008)	-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END